beta-Thromboglobulin: A platelet-specific protein which is released when platelets aggregate. Elevated plasma levels have been reported after deep venous thrombosis, pre-eclampsia, myocardial infarction with mural thrombosis, and myeloproliferative disorders. Measurement of beta-thromboglobulin in biological fluids by radioimmunoassay is used for the diagnosis and assessment of progress of thromboembolic disorders.Platelet Factor 4: A CXC chemokine that is found in the alpha granules of PLATELETS. The protein has a molecular size of 7800 kDa and can occur as a monomer, a dimer or a tetramer depending upon its concentration in solution. Platelet factor 4 has a high affinity for HEPARIN and is often found complexed with GLYCOPROTEINS such as PROTEIN C.Beta-Globulins: Serum proteins with an electrophoretic mobility that falls between ALPHA-GLOBULINS and GAMMA-GLOBULINS.Encyclopedias as Topic: Works containing information articles on subjects in every field of knowledge, usually arranged in alphabetical order, or a similar work limited to a special field or subject. (From The ALA Glossary of Library and Information Science, 1983)Blood Platelets: Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation.Platelet Activation: A series of progressive, overlapping events, triggered by exposure of the PLATELETS to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable hemostatic plug.Fibrinopeptide A: Two small peptide chains removed from the N-terminal segment of the alpha chains of fibrinogen by the action of thrombin during the blood coagulation process. Each peptide chain contains 18 amino acid residues. In vivo, fibrinopeptide A is used as a marker to determine the rate of conversion of fibrinogen to fibrin by thrombin.Cytoplasmic Granules: Condensed areas of cellular material that may be bounded by a membrane.Platelet Membrane Glycoproteins: Surface glycoproteins on platelets which have a key role in hemostasis and thrombosis such as platelet adhesion and aggregation. Many of these are receptors.Platelet Adhesiveness: The process whereby PLATELETS adhere to something other than platelets, e.g., COLLAGEN; BASEMENT MEMBRANE; MICROFIBRILS; or other "foreign" surfaces.Platelet Aggregation: The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS.Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.Consent Forms: Documents describing a medical treatment or research project, including proposed procedures, risks, and alternatives, that are to be signed by an individual, or the individual's proxy, to indicate his/her understanding of the document and a willingness to undergo the treatment or to participate in the research.Renal Dialysis: Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION.Renal Insufficiency, Chronic: Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)Search Engine: Software used to locate data or information stored in machine-readable form locally or at a distance such as an INTERNET site.Receptors, sigma: A class of cell surface receptors recognized by its pharmacological profile. Sigma receptors were originally considered to be opioid receptors because they bind certain synthetic opioids. However they also interact with a variety of other psychoactive drugs, and their endogenous ligand is not known (although they can react to certain endogenous steroids). Sigma receptors are found in the immune, endocrine, and nervous systems, and in some peripheral tissues.Databases, Genetic: Databases devoted to knowledge about specific genes and gene products.Genome, Human: The complete genetic complement contained in the DNA of a set of CHROMOSOMES in a HUMAN. The length of the human genome is about 3 billion base pairs.Myelin Basic Protein: An abundant cytosolic protein that plays a critical role in the structure of multilamellar myelin. Myelin basic protein binds to the cytosolic sides of myelin cell membranes and causes a tight adhesion between opposing cell membranes.Antibodies: Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)PubMed: A bibliographic database that includes MEDLINE as its primary subset. It is produced by the National Center for Biotechnology Information (NCBI), part of the NATIONAL LIBRARY OF MEDICINE. PubMed, which is searchable through NLM's Web site, also includes access to additional citations to selected life sciences journals not in MEDLINE, and links to other resources such as the full-text of articles at participating publishers' Web sites, NCBI's molecular biology databases, and PubMed Central.Sleep Apnea Syndromes: Disorders characterized by multiple cessations of respirations during sleep that induce partial arousals and interfere with the maintenance of sleep. Sleep apnea syndromes are divided into central (see SLEEP APNEA, CENTRAL), obstructive (see SLEEP APNEA, OBSTRUCTIVE), and mixed central-obstructive types.Sleep Apnea, Obstructive: A disorder characterized by recurrent apneas during sleep despite persistent respiratory efforts. It is due to upper airway obstruction. The respiratory pauses may induce HYPERCAPNIA or HYPOXIA. Cardiac arrhythmias and elevation of systemic and pulmonary arterial pressures may occur. Frequent partial arousals occur throughout sleep, resulting in relative SLEEP DEPRIVATION and daytime tiredness. Associated conditions include OBESITY; ACROMEGALY; MYXEDEMA; micrognathia; MYOTONIC DYSTROPHY; adenotonsilar dystrophy; and NEUROMUSCULAR DISEASES. (From Adams et al., Principles of Neurology, 6th ed, p395)Periodicals as Topic: A publication issued at stated, more or less regular, intervals.Fibrinolysis: The natural enzymatic dissolution of FIBRIN.Sleep: A readily reversible suspension of sensorimotor interaction with the environment, usually associated with recumbency and immobility.Polysomnography: Simultaneous and continuous monitoring of several parameters during sleep to study normal and abnormal sleep. The study includes monitoring of brain waves, to assess sleep stages, and other physiological variables such as breathing, eye movements, and blood oxygen levels which exhibit a disrupted pattern with sleep disturbances.Sarcoma, YoshidaHypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.JapanAntihypertensive Agents: Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.Societies, Medical: Societies whose membership is limited to physicians.Angiolymphoid Hyperplasia with Eosinophilia: Solitary or multiple benign cutaneous nodules comprised of immature and mature vascular structures intermingled with endothelial cells and a varied infiltrate of eosinophils, histiocytes, lymphocytes, and mast cells.Epinephrine: The active sympathomimetic hormone from the ADRENAL MEDULLA. It stimulates both the alpha- and beta- adrenergic systems, causes systemic VASOCONSTRICTION and gastrointestinal relaxation, stimulates the HEART, and dilates BRONCHI and cerebral vessels. It is used in ASTHMA and CARDIAC FAILURE and to delay absorption of local ANESTHETICS.Platelet Function Tests: Laboratory examination used to monitor and evaluate platelet function in a patient's blood.Platelet Count: The number of PLATELETS per unit volume in a sample of venous BLOOD.Bleeding Time: Duration of blood flow after skin puncture. This test is used as a measure of capillary and platelet function.Nucleic Acid Probes: Nucleic acid which complements a specific mRNA or DNA molecule, or fragment thereof; used for hybridization studies in order to identify microorganisms and for genetic studies.Parathyroid Glands: Two pairs of small oval-shaped glands located in the front and the base of the NECK and adjacent to the two lobes of THYROID GLAND. They secrete PARATHYROID HORMONE that regulates the balance of CALCIUM; PHOSPHORUS; and MAGNESIUM in the body.Amino Acid Sequence: The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.Bone and Bones: A specialized CONNECTIVE TISSUE that is the main constituent of the SKELETON. The principle cellular component of bone is comprised of OSTEOBLASTS; OSTEOCYTES; and OSTEOCLASTS, while FIBRILLAR COLLAGENS and hydroxyapatite crystals form the BONE MATRIX.Peptide Nucleic Acids: DNA analogs containing neutral amide backbone linkages composed of aminoethyl glycine units instead of the usual phosphodiester linkage of deoxyribose groups. Peptide nucleic acids have high biological stability and higher affinity for complementary DNA or RNA sequences than analogous DNA oligomers.Patents as Topic: Exclusive legal rights or privileges applied to inventions, plants, etc.Parathyroid Hormone: A polypeptide hormone (84 amino acid residues) secreted by the PARATHYROID GLANDS which performs the essential role of maintaining intracellular CALCIUM levels in the body. Parathyroid hormone increases intracellular calcium by promoting the release of CALCIUM from BONE, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates.Norethindrone: A synthetic progestational hormone with actions similar to those of PROGESTERONE but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used in treating amenorrhea, functional uterine bleeding, endometriosis, and for contraception.Tablets: Solid dosage forms, of varying weight, size, and shape, which may be molded or compressed, and which contain a medicinal substance in pure or diluted form. (Dorland, 28th ed)Estradiol: The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.Mestranol: The 3-methyl ether of ETHINYL ESTRADIOL. It must be demethylated to be biologically active. It is used as the estrogen component of many combination ORAL CONTRACEPTIVES.Ethinyl Estradiol: A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES.Contraceptives, Oral, Synthetic: Oral contraceptives which owe their effectiveness to synthetic preparations.Norgestrel: A synthetic progestational agent with actions similar to those of PROGESTERONE. This racemic or (+-)-form has about half the potency of the levo form (LEVONORGESTREL). Norgestrel is used as a contraceptive, ovulation inhibitor, and for the control of menstrual disorders and endometriosis.

NMR structure and dynamics of monomeric neutrophil-activating peptide 2. (1/247)

Neutrophil-activating peptide 2 (NAP-2), which demonstrates a range of proinflammatory activities, is a 72-residue protein belonging to the alpha-chemokine family. Although NAP-2, like other alpha-chemokines, is known to self-associate into dimers and tetramers, it has been shown that the monomeric form is physiologically active. Here we investigate the solution structure of monomeric NAP-2 by multi-dimensional 1H-NMR and 15N-NMR spectroscopy and computational modelling. The NAP-2 monomer consists of an amphipathic, triple-stranded, anti-parallel beta-sheet on which is folded a C-terminal alpha-helix and an aperiodic N-terminal segment. The backbone fold is essentially the same as that found in other alpha-chemokines. 15N T1, T2 and nuclear Overhauser effects (NOEs) have been measured for backbone NH groups and used in a model free approach to calculate order parameters and conformational exchange terms that map out motions of the backbone. N-terminal residues 1 to 17 and the C-terminus are relatively highly flexible, whereas the beta-sheet domain forms the most motionally restricted part of the fold. Conformational exchange occurring on the millisecond time scale is noted at the top of the C-terminal helix and at proximal residues from beta-strands 1 and 2 and the connecting loop. Dissociation to the monomeric state is apparently responsible for increased internal mobility in NAP-2 compared with dimeric and tetrameric states in other alpha-chemokines.  (+info)

In vitro antibacterial activities of platelet microbicidal protein and neutrophil defensin against Staphylococcus aureus are influenced by antibiotics differing in mechanism of action. (2/247)

Thrombin-induced platelet microbicidal protein-1 (tPMP-1) and human neutrophil defensin-1 (HNP-1) are small, cationic antimicrobial peptides. These peptides exert potent in vitro microbicidal activity against a broad spectrum of human pathogens, including Staphylococcus aureus. Evidence suggests that tPMP-1 and HNP-1 target and disrupt the bacterial membrane. However, it is not yet clear whether membrane disruption itself is sufficient to kill the bacterium or whether subsequent, presumably intracellular, events are also involved in killing. We investigated the staphylocidal activities of tPMP-1 and HNP-1 in the presence or absence of pretreatment with antibiotics that differ in their mechanisms of action. The staphylocidal effects of tPMP-1 and HNP-1 on control cells (no antibiotic pretreatment) were rapid and concentration dependent. Pretreatment of S. aureus with either penicillin or vancomycin (bacterial cell wall synthesis inhibitors) significantly enhanced the anti-S. aureus effects of tPMP-1 compared with the effects against the respective control cells over the entire tPMP-1 concentration range tested (P < 0.05). Similarly, S. aureus cells pretreated with these antibiotics were more susceptible to HNP-1 than control cells, although the difference in the effects against cells that received penicillin pretreatment did not reach statistical significance (P < 0.05 for cells that received vancomycin pretreatment versus effects against control cells). Studies with isogenic pairs of strains with normal or deficient autolytic enzyme activities demonstrated that enhancement of S. aureus killing by cationic peptides and cell wall-active agents could not be ascribed to a predominant role of autolytic enzyme activation. Pretreatment of S. aureus cells with tetracycline, a 30S ribosomal subunit inhibitor, significantly decreased the staphylocidal effect of tPMP-1 over a wide peptide concentration range (0.16 to 1.25 microgram/ml) (P < 0.05). Furthermore, pretreatment with novobiocin (an inhibitor of bacterial DNA gyrase subunit B) and with azithromycin, quinupristin, or dalfopristin (50S ribosomal subunit protein synthesis inhibitors) essentially blocked the S. aureus killing resulting from exposure to tPMP-1 or HNP-1 at most concentrations compared with the effects against the respective control cells (P < 0.05 for a tPMP-1 concentration range of 0.31 to 1.25 microgram/ml and for an HNP-1 concentration range of 6.25 to 50 microgram/ml). These findings suggest that tPMP-1 and HNP-1 exert anti-S. aureus activities through mechanisms involving both the cell membrane and intracellular targets.  (+info)

Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human ex vivo model of arterial thrombosis. (3/247)

Polyethylene glycol (PEG)-hirudin is a derivative of hirudin with a long plasma half-life. We have compared the efficacy of PEG-hirudin with unfractionated heparin (UH) in preventing arterial thrombosis. Arterial thrombus formation was induced ex vivo in 12 healthy human volunteers by exposing a tissue factor-coated coverslip positioned in a parallel-plate perfusion chamber to flowing nonanticoagulated human blood drawn directly from an antecubital vein at an arterial wall shear rate of 2600 s-1 for 3.5 minutes. PEG-hirudin, UH, or saline (as control) were administered ex vivo through a heparin-coated mixing device positioned proximal to the perfusion chamber. Platelet and fibrin deposition was quantified by immunoenzymatic measure of the P-selectin and D-dimer content of dissolved plasmin-digested thrombi, respectively. UH was administered to a plasma concentration of 0.35 IU/mL. This concentration prolonged the activated partial thromboplastin time from 32+/-1 seconds to 79+/-4 seconds (P<0.01). UH did not significantly prevent platelet deposition. However, fibrin deposition was reduced by 39% (P<0.05). PEG-hirudin in plasma concentrations of 0.5, 2.5, and 5 microg/mL prolonged the activated partial thromboplastin time to 48+/-2, 87+/-4, and 118+/-4 seconds, respectively. In contrast to UH, PEG-hirudin prevented both platelet and fibrin deposition in a dose-dependent manner with a >80% reduction at 5 microg/mL (P<0.01). Furthermore, the plasma level of PEG-hirudin required to significantly prevent fibrin deposition (0.5 microg/mL) corresponded to a much shorter prolongation of activated partial thromboplastin time (48+/-2 seconds) than that needed for UH (79+/-4 seconds). Thus, our results are compatible with the view that thrombin is greatly involved in recruitment of platelets in evolving thrombi, and that PEG-hirudin is an effective agent for preventing arterial thrombosis in a human ex vivo experimental model.  (+info)

Large amounts of vascular endothelial growth factor at the site of hemostatic plug formation in vivo. (4/247)

Vascular endothelial growth factor (VEGF) is important for the proliferation, differentiation, and survival of microvascular endothelial cells. It is a potent angiogenic factor and a specific endothelial cell mitogen that increases fenestration and extravasation of plasma macromolecules. Recently, large quantities of VEGF were detected in human megakaryocytes. Incubation of human platelets with thrombin in vitro resulted in the release of large amounts of VEGF. To investigate whether VEGF is released from platelets during coagulation activation in vivo, we measured in human subjects VEGF at the site of plug formation, ie, in blood emerging from a standardized injury made to determine bleeding time (shed blood). VEGF was also determined in the same volunteers after treatment with the specific thrombin inhibitor recombinant hirudin (r-hirudin). In a double-blind, randomized, crossover study, 17 healthy male volunteers (aged 20 to 35 years) were investigated. VEGF concentrations were measured in venous blood and in shed blood by the use of an immunoassay 10 minutes after intravenous administration of r-hirudin (0.35 mg/kg of body weight) or physiological saline. Prothrombin fragment f1.2 (f1.2) and beta-thromboglobulin (beta-TG) were determined as indicators of coagulation and platelet activation, respectively. Concentrations of VEGF, f1.2, and beta-TG in shed blood 4 minutes after injury were significantly higher than in venous blood (VEGF, 55.8+/-9.2 versus <20 pg/mL, P<0.001; f1.2, 71.3+/-10.4 versus 0.78+/-0.03 nmol/L, P<0. 001; beta-TG, 2290+/-170 versus 53.2+/-14.0 ng/mL, P<0.001). Administration of r-hirudin caused a >50% inhibition of the beta-TG and f1.2 levels in shed blood. In a similar manner, much lower amounts of VEGF were detectable at the site of plug formation after r-hirudin treatment (69.0+/-9.5 versus 37.8+/-2.6 pg/mL per minute; P=0.0015). Our data indicate that substantial quantities of VEGF are released from platelets during the interaction with the injured vessel wall in vivo. This finding may be relevant with respect to wound healing and tissue repair, tumor vascularization, or arterial thrombus formation.  (+info)

Increased formation of thromboxane in vivo in humans with mastocytosis. (5/247)

Clinical manifestations of mastocytosis are mediated, at least in part, by release of the mast cell mediators histamine and prostaglandin D2. It has been previously reported that in addition to prostaglandin D2, mast cells produce other eicosanoids, including thromboxane. Nonetheless, little information exists regarding the formation of other prostanoids in vivo. The most accurate method to examine the systemic production of eicosanoids in vivo is the quantitation of urinary metabolites. We previously developed a highly accurate assay employing mass spectrometry to measure a major urinary metabolite of thromboxane, 11-dehydro-thromboxane B2, in humans. We utilized this assay to quantitate thromboxane production in 17 patients with histologically proven mastocytosis. We report that thromboxane formation was significantly increased (>2 SD above the mean) in at least one urine sample from 65% of patients studied. Of these, 91% of patients with documented systemic involvement had elevated thromboxane generation. In addition, endogenous formation of thromboxane was highly correlated with the urinary excretion of the major urinary metabolite of prostaglandin D2 (r = 0.98) and Ntau-methylhistamine (r = 0.91), suggesting that the cellular source of increased thromboxane in vivo could be the mastocyte. Enhanced thromboxane formation in patients with this disorder is unlikely to be of platelet origin as other markers of platelet activation, platelet factor 4 and beta-thromboglobulin, were not increased in three patients with marked overproduction of thromboxane. Furthermore, the recovery of 11-dehydro-thromboxane B2 excretion in two patients after the administration of aspirin occurred significantly more rapidly than the recovery of platelet thromboxane generation. These studies, therefore, report that thromboxane production is significantly increased in the majority of patients with mastocytosis that we examined and provide the basis to elucidate the role of this eicosanoid in disorders of mast cell activation.  (+info)

Changes of hemostasis, endogenous fibrinolysis, platelet activation and endothelins after percutaneous transluminal coronary angioplasty in patients with stable angina. (6/247)

OBJECTIVES: This study investigated parameters of endogenous fibrinolysis, activation of coagulation and platelets, and endothelin levels before and after elective percutaneous transluminal coronary angioplasty (PTCA) in patients with stable coronary artery disease (CAD). BACKGROUND: Abrupt vessel closure is a serious short-term complication after PTCA and is often unforeseeable. Detailed insight into the effect of PTCA on hemostasis, platelets and the release of vasoconstrictive substances, which are among the mainly discussed mechanisms of abrupt vessel closure, is needed to enhance the safety of coronary intervention. METHODS: Plasma levels of markers of platelet activity, coagulation, endogenous fibrinolysis and endothelins were determined in 20 patients with stable CAD undergoing elective PTCA. The blood specimens were drawn before, immediately after, 1 h after intervention and on the next morning. RESULTS: All patients showed an initially uncomplicated PTCA. Regarding the efficacy of anticoagulation after receiving 15.000 IU heparin during PTCA, two groups were compared. In eight patients with ineffective anticoagulation production of thrombin and platelet activation directly after and 1 h after PTCA was significantly higher compared with 12 patients with effective anticoagulation. Despite the strong activation of coagulation, only a low fibrinolytic response could be observed. Endothelins rose significantly after PTCA in both groups but stayed longer on higher levels in patients with distinct thrombin generation. Three of the eight patients without sufficient heparin treatment suffered abrupt vessel closure. CONCLUSIONS: Initially uncomplicated dilation of coronary arteries leads to systemically measurable activation of coagulation and platelets in patients with ineffective doses of heparin and release of endothelins in all patients. Therefore, individual adjustment of anticoagulation and platelet inhibition in combination with effective antivasospastic substances are needed in every patient before, during and after initially uncomplicated PTCA to prevent this serious complication.  (+info)

Plasmid-mediated resistance to thrombin-induced platelet microbicidal protein in staphylococci: role of the qacA locus. (7/247)

Thrombin-induced platelet microbicidal protein 1 (tPMP-1) is a small, cationic peptide released from rabbit platelets following thrombin stimulation. In vitro resistance to this peptide among strains of Staphylococcus aureus correlates with the survival advantage of such strains at sites of endothelial damage in humans as well as in experimental endovascular infections. The mechanisms involved in the phenotypic resistance of S. aureus to tPMP-1 are not fully delineated. The plasmid-encoded staphylococcal gene qacA mediates multidrug resistance to multiple organic cations via a proton motive force-dependent efflux pump. We studied whether the qacA gene might also confer resistance to cationic tPMP-1. Staphylococcal plasmids encoding qacA were found to confer resistance to tPMP-1 in an otherwise susceptible parental strain. Deletions which removed the region containing the qacA gene in the S. aureus multiresistance plasmid pSK1 abolished tPMP-1 resistance. Resistance to tPMP-1 in the qacA-bearing strains was inoculum independent but peptide concentration dependent, with the level of resistance decreasing at higher peptide concentrations for a given inoculum. There was no apparent cross-resistance in qacA-bearing strains to other endogenous cationic antimicrobial peptides which are structurally distinct from tPMP-1, including human neutrophil defensin 1, protamine, or the staphylococcal lantibiotics pep5 and nisin. These data demonstrate that the staphylococcal multidrug resistance gene qacA also mediates in vitro resistance to cationic tPMP-1.  (+info)

PDGF-AB release during and after haemodialysis procedure. (8/247)

BACKGROUND: During haemodialysis blood membrane contact causes the release of the content of platelet alpha-granules, which contain platelet-derived growth factor (PDGF). In view of its possible role in accelerated atherosclerotic processes, we evaluated the intra- and post-dialytic changes in PDGF-AB serum levels during haemodialysis sessions performed using a cellulosic membrane. METHODS: Using the ELISA method, PDGF-AB, platelet factor-4 (PF4) and beta-thromboglobulin (beta-TG) levels were determined in peripheral blood, as well as in arterial and venous haemodialyser lines, in 10 patients each of whom underwent five consecutive dialysis sessions with a CU membrane. Blood samples were taken at 0, 15, 30, 60, 120, 180 and 240 min during dialysis and at 1, 4 and 20 h after the end of the session. In the same group of patients the levels of the same molecules were also determined after a heparin bolus injection of 4500 IU, blood samples were taken at 0, 15 and 30 min after injection of the bolus. RESULTS: PDGF-AB serum levels increased, remained consistently high during the haemodialysis session (in particular +134+/-20% after 30 min, P<0.001, and +140+/-5% after 240 min, P<0.001) and returned to basal values only after 20 h following the end of the session. PF4 and beta-TG showed a similar trend to PDGF. The heparin bolus injection caused only a small increase (+15+/-5% at 30 min) in PDGF-AB serum levels. CONCLUSIONS: PDGF-AB is released during dialysis mainly as consequence of the blood-membrane contact and it returns only slowly to basal values.  (+info)

Looking for online definition of platelet basic protein in the Medical Dictionary? platelet basic protein explanation free. What is platelet basic protein? Meaning of platelet basic protein medical term. What does platelet basic protein mean?
Beta-thromboglobulin (β-thromboglobulin, also called Pro-Platelet basic protein) is a protein that is stored in alpha-granules of platelets and released in large amounts after platelet activation. It is a type of Chemokine (C-X-C motif) ligand 7. It is a chemoattractant, strongly for fibroblasts and weakly for neutrophils. It is a stimulator of mitogenesis, extracellular matrix synthesis, glucose metabolism, and plasminogen activator synthesis in human fibroblasts. Beta-Thromboglobulin also affects megakaryocyte maturation, and thus helps in regulating platelet production. Levels of Beta-Thromboglobulin is used to index platelet activation. It is measured by ELISA in blood plasma or urine, and often in conjunction with Platelet factor 4) It is elevated in diabetes mellitus. Cytokines & Cells Online Pathfinder Encyclopaedia Beta-Thromboglobulin Retrieved on August 17, 2009 Pillai MM, Iwata M, Awaya N, Graf L, Torok-Storb B (May 2006). "Monocyte-derived CXCL7 peptides in the marrow ...
Plasma beta-thromboglobulin is correlated with platelet adhesiveness to bovine endothelium in patients with diabetes mellitus.: We measured simultaneous plasma
Abstract Introduction: The role of platelet activation in allergic inflammation is receiving increasing attention. Sublingual immunotherapy for allergic rhinitis can modify the immunological process to an allergen, rather than simply treating symptoms. Objective: The aim of this study was to explore the role of platelet activation during sublingual immunotherapy in children with allergic rhinitis. Methods: Forty-two House Dust Mite - sensitized children with allergic rhinitis were enrolled and received House Dust Mite allergen extract for sublingual immunotherapy or placebo. Serum of different time points during treatment was collected and used for detection of Platelet Factor-4 and Beta-Thromboglobulin concentration by Enzyme-Linked Immuno Sorbent Assay. Results: Our data showed decreased expression of Platelet Factor-4 and Beta-Thromboglobulin protein after one years sublingual immunotherapy. In addition, the decrease of symptom scores and serum Platelet Factor-4 and Beta-Thromboglobulin protein
The use of RT-PCR to obtain quantitative data regarding the expression of the transgene relative to an endogenous gene requires comparison of products at points when both are in the linear range of amplification. For quantitative studies, the antisense primers were 5′-labeled with fluorescent dye Cy-5 (Integrated DNA Technologies, Coralville, IA). Preliminary experiments showed that the human and mouse PCR products were in the linear range of amplification between cycles 14 to 20. Therefore, PCR reaction mixtures were typically divided into several 15-μL aliquots before initiation of the reaction. PCR was performed at 94°C for 2 minutes, followed by cycles at 94°C for 25 seconds, 50°C for 40 seconds, and 72°C for 40 seconds in a PTC-100 Programmable Thermal Controller (MJ Research, Watertown, MA). At selected cycles aliquots from hPF4 and mPF4 or hPBP and mPBP reactions were removed from the thermocycler and placed on ice. The Cy-5-labeled products were then run on a 10% TBE Ready Gel ...
Oryctolagus cuniculus platelet microbicidal protein: platelet alpha-granule derived protein; bactericidal for common infective endocarditis pathogens; the protein plus oxacillin exert a synergistic bacterial effect
UCL Discovery is UCLs open access repository, showcasing and providing access to UCL research outputs from all UCL disciplines.
Human blood platelets were stored for five days as concentrates in 60 mL of: (a) plasma; (b) non-plasma medium with anticoagulant; and (c) non-plasma medium without anticoagulant. All preparations were equally functional when tested for platelet aggregation and release reaction in response to single agonist or synergistic pairs of agonists in vitro. Platelets stored in non-plasma medium with anti-coagulant had lower kallikrein, fibrino(gen)peptide A, lactate, and beta-thromboglobulin than did plasma controls after five days. In vivo recovery and survival of platelets stored in non-plasma medium with anticoagulant were 51.2% +/- 4.3% and 8.7 +/- 0.3 days, respectively, which were not statistically different from plasma controls of 39.2% +/- 4.9% and 7.2 +/- 0.8 days, respectively. It is concluded that platelets can be stored for five days in a non-plasma medium and still have good in vivo recoveries and survivals. ...
Six consecutive hemodialysis (HD) sessions are evaluated per patient, altogether 10 - 12 stable HD patients (or at least 48 HD sessions altogether). During these six sessions, AN69ST and Fx8 are used on alternate days. Dalteparin is given intravenously as a single bolus dose at start of HD (50% of the conventional dose). Clinical clotting is evaluated visually each hour of HD after blood draining of the venous air trap: 1=no clot, 2=a fibrinous ring, 3=a clot ,1 cm, 4=a clot ,1 cm and 5=coagulated system (stop in HD).. Blood specimens are taken at start and after each hour of HD. Markers of coagulation (prothrombin 1+2) and of platelets (beta-thromboglobulin) are evaluated as well as anti FXa-activity.. The two filters are going to be compared statistically with respect to the degree of clinical clotting and of intravascular coagulation and platelets activation. ...
The activation of platelets in response to vascular injury or inflammation leads to the secretion of a variety of mediators, which modulate the functions of inflammatory cells. Platelet Factor 4 (PF4) is a platelet-specific protein member of the chemokine superfamily. Although the capacity of PF4 as an antiangiogenic factor or its procoagulant activity are well established, little is known about its proinflammatory functions. In the present study, we demonstrate the ability of PF4 to activate resting Natural Killer cells, to synthesize proinflammatory cytokines, such as IL-8, IL-1-beta, IL-6, IFN-gamma, TNF-alpha and granulocyte/macrophage colony-stimulatory factor (GM-CSF). Dose-response curves (10-200 ng/ml) and time-course assays show that PF4 increases mRNA levels and protein release for all cytokines studied. This ability was retained even while PF4 was bound to heparin, the physiological conditions must to greate affinity to glycosaminoglycans of the endotelial cells surface. Stimulation ...
Whereas in vitro studies showed that plasmin may induce both inhibition and activation of platelets, in vivo and ex vivo investigations suggested that thrombolytic agents are responsible for platelet stimulation. To gain further information on this topic, ex vivo platelet function was studied in 24 subjects with acute myocardial infarction treated with streptokinase or recombinant tissue-type plasminogen activator (rt-PA). Ten patients with acute myocardial infarction who did not receive thrombolytic treatment were also investigated. The data shows that at the end of thrombolytic infusion, the maximal extent of platelet aggregation and adenosine triphosphate release was reduced in treated patients compared with that in untreated ones. In subjects treated with streptokinase, the defect in platelet aggregation derived from both cellular and plasmatic defects. Plasmatic beta-thromboglobulin concentration was significantly reduced after streptokinase, but unchanged after rt-PA. Three days after ...
MAA370Ra22, Monoclonal Antibody to Beta-Thromboglobulin (bTG), β-血小板球蛋白(bTG)单克隆抗体, CXCL7; PPBP; PBP; B-TG1; CTAP-III; CTAP3; CTAPIII; LA-PF4; LDGF; MDGF; NAP2; SCYB7; TC1; TC2; TGB1; THBGB1; Pro-Platelet Basic Protein; Chemokine C-X-C-Motif Ligand 7 | 仅供体外研究使用,不用于临床诊断!请索取进口关税税单及报关单!
RESEARCH DESIGN AND METHODS Fifty patients and 50 comparable control subjects were enrolled in this study. The patients were subdivided in two groups, according to their level of HbA1c (group 1, n = 30, HbA1c ≤ 8% group 2, n = 20, HbA1c , 8%). We determined the platelet count, the platelet aggregation in the spontaneous state and in the presence of ADP or collagen, β-thromboglobulin, platelet factor 4, fibrinogen, von Willebrand factor (factors VIII:C, VIIIR:Ag, and VIIIR:VW), plasma and urinary fibrinopeptide A, euglobulin lysis time, anticoagulant proteins C and S, and plasma viscosity.. ...
Reactome is pathway database which provides intuitive bioinformatics tools for the visualisation, interpretation and analysis of pathway knowledge.
Reactome is pathway database which provides intuitive bioinformatics tools for the visualisation, interpretation and analysis of pathway knowledge.
Chemokine ligand 5 is a small cytokine belonging to the CXC chemokine family that is also known as epithelial-derived neutrophil-activating peptide 78.
CXCL5 protein is expressed in E. coli, processed, refolded and purified to yield the native, secreted form of the mature chemokine. C-X-C motif chemokine 5 (CXCL5) or epithelial-derived neutrophil-activating peptide 78 (ENA-78) is a protein that in humans
Neutrophil-activating protein-2 (NAP-2) is a 72 residue protein demonstrating a range of proinflammatory activities. The solution structure of monomeric NAP-2 has been investigated by two-dimensional 1H-n.m.r. spectroscopy. Sequence-specific proton resonance assignments have been made and secondary structural elements have been identified on the basis of nuclear Overhauser data, coupling constants and amide hydrogen/deuteron exchange. The NAP-2 monomer consists of a triple-stranded anti-parallel beta-sheet arranged in a Greek key and a C-terminal helix (residues 59-70) and is very similar to that found in the n.m.r. solution conformation of dimeric interleukin-8 and the crystal structure of tetrameric bovine platelet factor-4. Results are discussed in terms of heparin binding and neutrophil-activation properties of NAP-2. ...
In patients with acute stroke, increased75,76,77,78 or abnormally low78,79 secretion of ACTH and cortisol are associated with larger infarctions, poorer functional outcome, and increased mortality, indicating that both extremes of the HPA axis response may be deleterious. Patients with increased cortisol may have a strong inflammatory response, with increased temperature, fibrinogen, white blood cell counts, β-thromboglobulin, and IL-6 levels.79,80 High cortisol has also been associated in some studies,81 but not in others,81,82 with higher catecholamine excretion, and frontal lobe, or insular infarctions.83,84 Unfortunately, the rate of infection and immune competence were not described in the patients included in these studies.. In brain ischemic mice, stroke induces a long-lasting depression of the cell-mediated immunity, including monocyte deactivation, lymphopenia, and a Th1/Th2 shift associated with spontaneous bacteremia and pneumonia.85 In mice, focal cerebral ischemia also reduces ...
SEA080Hu, ELISA Kit for Interleukin 8 (IL8), Homo sapiens (Human), Sandwich ELISA, CXCL8, AMCF-I, GCP1, K60, LECT, LUCT, LYNAP, MDNCF, MONAP, NAF, NAP1, SCYB8, TSG1, B-ENAP, Neutrophil-Activating Protein 1, Granulocyte Chemotactic Protein 1, Designed by Cloud-Clone Corp.
Ischemic stroke is major cause of disability and mortality worldwide, and aging is strong risk factor for poor post-stroke outcome. Neutrophils traffic rapidly to the brain following ischemic stroke, and recent evidence has suggested that aging may alter neutrophil function after tissue injury. In this study, we hypothesize that aging enhances the pro-inflammatory function of neutrophils, directly contributing to the poorer outcomes seen in aging patients. We utilized demographic data and biological specimens from ischemic stroke patients and an experimental mouse model to determine the correlation between age, neutrophil function and stroke outcomes. In ischemic stroke patients, age was associated with increased mortality and morbidity and higher levels of neutrophil-activating cytokines. In mice, aged animals had higher stroke mortality and morbidity, higher levels of neutrophil-activating cytokines and enhanced generation of neutrophil reactive oxygen species compared to young mice. Finally,
blood microparticle, extracellular exosome, extracellular matrix, extracellular region, extracellular space, ficolin-1-rich granule lumen, platelet alpha granule lumen, secretory granule lumen, neutrophil degranulation, platelet degranulation
A CXC chemokine that is found in the alpha granules of PLATELETS. The protein has a molecular size of 7800 kDa and can occur as a monomer, a dimer or a tetramer depending upon its concentration in solution. Platelet factor 4 has a high affinity for HEPARIN and is often found complexed with GLYCOPROTEINS such as PROTEIN C ...
References for Abcams Recombinant human GRO alpha protein (ab73810). Please let us know if you have used this product in your publication
The Steam Turbine and Governor block implements a complete tandem-compound steam prime mover, including a speed governing system, a four-stage steam turbine, and a shaft with up to four masses.
Chemokine (C-X-C motif) ligand 1 (CXCL1) is a small cytokine belonging to the CXC chemokine family that was previously called GRO1 oncogene, GROα, KC, Neutrophil-activating protein 3 (NAP-3) and melanoma growth stimulating activity, alpha (MSGA-α). In humans, this protein is encoded by the CXCL1 gene.
Ajou University Medical Information & Media Center 164 Worldcup-ro Yeongtong-gu Suwon 16499 Korea / TEL : 031-219-5312 / FAX : 031-219- ...
Abcams GRO alpha ELISA Kit suitable for Cell culture supernatant, Serum, Plasma in mouse. Reliably quantify 1 pg/ml of GRO alpha.
小鼠GRO alpha ELISA试剂盒(CXCL1) ELISA试剂盒datasheet (ab100717).Abcam抗体、ELISA、激动剂拮抗剂、表观遗传试剂、蛋白多肽,使用效果保证,中国70%以上现货。
EK2875小鼠P选择素(P-Selectin/CD62P)ELISA试剂盒MouseP-SelectinELISAkitEK2876小鼠血小板衍生生长因子AB(PDGF-AB)ELISA试剂盒MousePlatelet-DerivedGrowthFactorAB,PDGF-ABELISAkitEK2877小鼠血小板衍生生长因子可溶性受体α(PDGFsR-α)ELISA试剂盒MousePlatel
We have emailed you at with instructions on how to set up a new password. If you do not receive an email in the next 24 hours, or if you misplace your new password, please contact:. ASA members: ...
Looking for online definition of neutrophil microbicidal assay in the Medical Dictionary? neutrophil microbicidal assay explanation free. What is neutrophil microbicidal assay? Meaning of neutrophil microbicidal assay medical term. What does neutrophil microbicidal assay mean?
Definition of neutrophil microbicidal assay in the Legal Dictionary - by Free online English dictionary and encyclopedia. What is neutrophil microbicidal assay? Meaning of neutrophil microbicidal assay as a legal term. What does neutrophil microbicidal assay mean in law?
Reaktivität: Huhn, Rind (Kuh), Hund and more. 104 verschiedene PF4 ELISA Kits vergleichen. Alle direkt auf antikoerper-online.de bestellbar!
RPA172Mu02, Recombinant Platelet Factor 4 (PF4), 血小板因子4(PF4)重组蛋白, CXCL4; SCYB4; Chemokine C-X-C-Motif Ligand 4; Oncostatin-A; Iroplact | 仅供体外研究使用,不用于临床诊断!请索取进口关税税单及报关单!
The reliability of implantable blood sensors is often hampered by unspecific adsorption of plasma proteins and blood cells. This not only leads to a loss of sensor signal over time, but can also result in undesired host vs. graft reactions. Within this study we evaluated the hemocompatibility of isocyanate conjugated star shaped polytheylene oxide-polypropylene oxide co-polymers NCO-sP(EO-stat-PO) when applied to gold surfaces as an auspicious coating material for gold sputtered blood contacting sensors. Quartz crystal microbalance (QCM) sensors were coated with ultrathin NCO-sP(EO-stat-PO) films and compared with uncoated gold sensors. Protein resistance was assessed by QCM measurements with fibrinogen solution and platelet poor plasma (PPP), followed by quantification of fibrinogen adsorption. Hemocompatibility was tested by incubation with human platelet rich plasma (PRP). Thrombin antithrombin-III complex (TAT), β-thromboglobulin (β-TG) and platelet factor 4 (PF4) were used as coagulation
Our studies demonstrate that H. pylori LPS stimulates the release of both neutrophil-activating, C-X-C chemokines (IL-8 and ENA-78) and the monocyte-activating C-C chemokine MCP-1 from human monocytes. These chemokines are potent leukocyte chemoattractants and may play an important role in regulating inflammatory cell infiltration of H. pylori-infected gastric mucosa (7, 11, 14, 15,20, 21, 23, 27, 37, 40, 48). We found that H. pyloriLPS is less potent than Salmonella lipid A in inducing monocyte chemokine production. This finding agrees with previous studies showing low potency for H. pylori LPS in the induction of a wide variety of host inflammatory responses (9, 18,19, 34, 36, 38, 39, 42). However, when the actions of H. pylori LPS were specifically inhibited by using either an LPS antagonist or CD14 receptor blockade, the monocyte-activating potential of H. pylori water extract was almost completely abolished. These findings suggest that H. pylori LPS may be the primary monocyte-activating ...
Erythromelalgia is the main, pathognomonic and presenting symptom in patients with Essential Thrombocythemia and thrombocythemia associated with Polycythemia Vera. Complete relief of erythromelalgic and acrocyanotic pain is obtained with the cyclooxygenase inhibitors aspirin and indomethacin, but not with sodiumsalicylate, dipyridamol, sulfinpyrozone and ticlopedine indicating that platelet-mediated cyclooxygenase metabolites are necessary for erythromelalgia to develop. Local platelet consumption in erythromelalgic areas became evident by the demonstration of arteriolar fibromuscular intimal proliferation and occlusions by platelet-rich thrombi in skin biopsies, by the findings of shortened platelet survival times, significant higher levels of platelet activation markers -thromboglobulin ( -TG), thrombomoduline and increased urinary thromboxane B2 excretion in thrombocythemia patients suffering from erythromelalgia. Aspirin treatment of erythromelalgia in thrombocythemia patients resulted in ...
Helicobacter pylori (H. pylori) is closely associated with chronic gastritis, peptic ulcer disease, and gastric adenocarcinoma and lymphoma. Helicobacter pylori neutrophil-activating protein (HP-NAP) is an important virulence factor of H. pylori for its pathogenesis. To investigate how HP-NAP activates human neutrophils, HP-NAP was expressed in Escherichia coli (E.coli), purified by the two sequential gel filtration chromatographies, and then subjected to filtration for the removal of endotoxin. The recombinant HP-NAP was able to stimulate human neutrophils to produce reactive oxygen species (ROS) as examined by luminol-enhanced chemiluminescent assay. HP-NAP can also promote the secretion of myeloperoxidase (MPO) in human neutrophils. The finding of this new function of HP-NAP in human neutrophils suggests that there should be more host immune responses of HP-NAP awaited to be explored ...
short-term fire fighting activity will result in: a) a reduction in arterial function (reduced endothelial function, increased augmentation index and an attenuated arterial stiffness response); b) a disruption in hemostasis that is characterized by an increase in platelet number and function, an increased coagulatory potential and altered fibrinolytic potential; and c) an elevation in procoagulatory cytokines, systemic inflammation, monokine chemoattractant protein, and matrix metalloproteinases ...
HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase inhibitors (statins) have been suggested to attenuate abdominal aortic aneurysm (AAA) growth. However, the effects of statins in human AAA tissues are not fully elucidated. The aim of this study was to investigate the direct effects of statins on proinflammatory molecules in human AAA walls in ex vivo culture. Simvastatin strongly inhibited the activation of nuclear factor (NF)-κB induced by tumor necrosis factor (TNF)-α in human AAA walls, but showed little effect on c-jun N-terminal kinase (JNK) activation. Simvastatin, as well as pitavastatin significantly reduced the secretion of matrix metalloproteinase (MMP)-9, monocyte chemoattractant protein (MCP)-2 and epithelial neutrophil-activating peptide (CXCL5) under both basal and TNF-α-stimulated conditions. Similar to statins, the Rac1 inhibitor NSC23766 significantly inhibited the activation of NF-κB, accompanied by a decreased secretion of MMP-9, MCP-2 and CXCL5. Moreover, the effect of
购买GRO gamma山羊多克隆抗体(ab10367),GRO gamma抗体经WB,ELISA验证,可与人,小鼠,大鼠样本反应。产品出库一年都在质保范围内。中国现货速达。
Essentially pure preparations of normal density eosinophils obtained from patients with hypereosinophilic syndrome (HES) were stimulated with complement factor 5a (C5a), platelet-activating factor (PAF), FMLP and neutrophil-activating peptide (NAP-1/IL-8). Three responses were studied, the transient rise in cytosolic free calcium concentration ([Ca2+]i) (derived from indo-1 fluorescence), shape changes (measured by laser turbidimetry), and exocytosis of eosinophil peroxidase (EPO) (assessed by H2O2/luminol-dependent chemiluminescence). Responses were obtained with all four agonists, but C5a and PAF were by far more potent than FMLP and NAP-1/IL-8, which induced only minor effects. Pretreatment of the cells with pertussis toxin attenuated [Ca2+]i changes, EPO release and, to a lesser extent, shape changes, indicating that GTP-binding proteins of Gi-type are involved in receptor-dependent signal transduction processes leading to these responses. A clear dissociation was observed in the control of ...
Antocijanini imaju tendenciju da budu glavni polifenoli u rozom grožđu dok su flavan-3-oli (i.e. katehini) zastupljeniji fenoli u belim varijetetima.[17] Ukupni fenolni sadržaj, laboratorijski indeks antioksidantske jačine, je veći u rozim varijetetima prevashodno usled antocijaninske gustine u ljusci crnog grožđa, u poređenju sa odsustvom antocijanina u ljusci belog grožđa.[17] Ovi antocijanini privlače napore naučnika da definišu njihove osobine u pogledu ljudskog zdravlja.[18] Fenolni sadržaj ljuske grožđa varira sa kultivarom, kompozicijom zemljišta, klimom, geografskim poreklom, i praksom kultivacije ili izloženosti bolestima, kao što su gljivične infekcije.. Crno vina mogu da ponude zdravstvene beneficije koje su veće od belog vina, zbog potencijalno korisnih jedinjenja koja su prisutna u ljusci grožđa, a samo crveno vino se fermentira sa ljuskom. Dužina fermentacionog perioda koje vino provede u kontaktu sa ljuskom grožđa je važna odrednica njegovog ...
With platelet activation, there is modulation of platelet surface molecule expression. In flow cytometric analyses of in vivo platelet activation, results are often confounded by activation induced in vitro by the preparative procedures. It is particularly important therefore to prevent or retard platelet activation as soon as possible after withdrawal of the blood sample. Taking blood into paraformaldehyde, or fixing the cells with paraformaldehyde as soon as possible after withdrawal, has been employed to prevent platelet activation in vitro, but paraformaldehyde-fixed platelets cannot be further used in functional studies. We investigated the efficacy of Diatube-H, a commercially available combination of platelet antagonists (theophylline, adenosine, and dipyridamole), in preventing or retarding platelet activation in vitro, along with its effects on modulation of platelet membrane glycoproteins (GP) and adhesion molecules. In contrast to blood taken into EDTA, blood taken into Diatube-H ...
Thank you for your interest in spreading the word about Biochemical Journal.. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.. ...
1F9R: Structure Comparison of Two Platelet Factor 4 Mutants with the Wild-type Reveals the Epitopes for the Heparin-induced Thrombocytopenia Antibodies
Mhedbi-Hajri N, Hajri A, Boureau T, Darrasse A, Durand K, Brin C, Saux MF, Manceau C, Poussier S, Pruvost O, Lemaire C, Jacques MA ...
It is an isoform of Beta-Thromboglobulin or Pro-Platelet basic protein (PPBP). It is a protein that is released in large ... Tunnacliffe A, Majumdar S, Yan B, Poncz M (1992). "Genes for beta-thromboglobulin and platelet factor 4 are closely linked and ... Majumdar S, Gonder D, Koutsis B, Poncz M (1991). "Characterization of the human beta-thromboglobulin gene. Comparison with the ... Majumdar S, Gonder D, Koutsis B, Poncz M (1991). "Characterization of the human beta-thromboglobulin gene. Comparison with the ...
1992). "A new assay for beta-thromboglobulin in urine.". Thromb. Res. 64 (1): 33-43. PMID 1837963. doi:10.1016/0049-3848(91) ... proinflamatorni citokin (IL-1, TNF-alfa) • Th1 (INF-gama i TNF-beta) • Th2 (IL-4, IL-5, IL-6, IL-10, IL-13) • Th17 (IL-17,IL-22 ... Tunnacliffe A, Majumdar S, Yan B, Poncz M (1992). "Genes for beta-thromboglobulin and platelet factor 4 are closely linked and ... Majumdar S, Gonder D, Koutsis B, Poncz M (1991). "Characterization of the human beta-thromboglobulin gene. Comparison with the ...
... a growth factor structurally related to beta-thromboglobulin". EMBO J. 7 (7): 2025-33. PMC 454478 . PMID 2970963. Omari KM, ... Becker S, Quay J, Koren HS, Haskill JS (March 1994). "Constitutive and stimulated MCP-1, GRO alpha, beta, and gamma expression ... capacity for immortalized melanocytes expressing melanoma growth stimulatory activity/growth-regulated cytokine beta and gamma ...
Reduced osmotic pressure will trigger the liver to produce more proteins like fibrinogen and beta-thromboglobulin, which ... Cystathionine beta synthase deficiency, also known as homocystinuria, is an autosomal recessive inherited disorder in which the ...
... beta-2 microglobulin MeSH D12.776.377.715.182.160 - beta-thromboglobulin MeSH D12.776.377.715.182.200 - complement factor h ... beta-thromboglobulin MeSH D12.776.467.374.200.100 - chemokines, c MeSH D12.776.467.374.200.110 - chemokines, cc MeSH D12.776. ... beta-crystallin a chain MeSH D12.776.306.366.300.200 - beta-crystallin b chain MeSH D12.776.331.199.750.500 - succinate ... thyroid hormone receptors beta MeSH D12.776.624.664.700.915 - RNA-binding protein FUS MeSH D12.776.624.664.700.957 - stathmin ...
... beta-2 microglobulin MeSH D12.776.124.790.223.160 -- beta-thromboglobulin MeSH D12.776.124.790.223.200 -- complement factor h ...
"Negative regulation of human megakaryocytopoiesis by human platelet factor 4 and beta thromboglobulin: comparative analysis in ...
... beta-thromboglobulin MeSH D23.125.300.100 --- chemokines, c MeSH D23.125.300.110 --- chemokines, cc MeSH D23.125.300.120 --- ... beta-thromboglobulin MeSH D23.469.200.100 --- chemokines, c MeSH D23.469.200.110 --- chemokines, cc MeSH D23.469.200.120 --- ... beta subunit, human MeSH D23.101.840.375 --- hormones, ectopic MeSH D23.101.840.400 --- ki-67 antigen MeSH D23.101.840.500 --- ... transforming growth factor beta MeSH D23.348.479.996 --- wnt proteins MeSH D23.348.479.996.500 --- wnt1 protein MeSH D23.348. ...
... beta-thromboglobulin MeSH D12.644.276.174.200.100 --- chemokines, c MeSH D12.644.276.174.200.110 --- chemokines, cc MeSH ... gtp-binding protein beta subunits MeSH D12.644.360.375.730 --- gtp-binding protein gamma subunits MeSH D12.644.360.375.940 --- ... beta-msh MeSH D12.644.400.460.115 --- gamma-msh MeSH D12.644.400.465 --- msh release-inhibiting hormone MeSH D12.644.400.470 ... beta-msh MeSH D12.644.548.691.525.690.583.115 --- gamma-msh MeSH D12.644.548.691.525.883 --- thyrotropin MeSH D12.644.548.691. ...
... (β-thromboglobulin, also called Pro-Platelet basic protein) is a protein that is stored in alpha-granules ... Beta-Thromboglobulin also affects megakaryocyte maturation, and thus helps in regulating platelet production. Levels of Beta- ... Cytokines & Cells Online Pathfinder Encyclopaedia --> Beta-Thromboglobulin Retrieved on August 17, 2009 Pillai MM, Iwata M, ... Thromboglobulin is used to index platelet activation. It is measured by ELISA in blood plasma or urine, and often in ...
... beta adrenergic receptor - beta sheet - beta-1 adrenergic receptor - beta-2 adrenergic receptor - beta-thromboglobulin - ... transforming growth factor beta - transforming growth factor beta receptor - transient receptor potential - translation ( ... alpha-beta T-cell antigen receptor - alpha-fetoprotein - alpha-globulin - alpha-macroglobulin - alpha-MSH - Ames test - amide ... interferon-beta - interleukin receptor - interleukin-1 receptor - interleukin-2 receptor - interleukin-3 - interleukin-3 ...
The other ADP-receptor P2Y1 couples to Gq that activates phospholipase C-beta 2 PLCB2, resulting in inositol 1,4,5- ... B-thromboglobulin, vWF, fibrinogen, and coagulation factors V and XIII. δ granules (delta or dense granules) - containing ADP ... Platelets release platelet-derived growth factor (PDGF), a potent chemotactic agent; and TGF beta, which stimulates the ...
The other ADP-receptor P2Y1 couples to Gq that activates phospholipase C-beta 2 PLCB2, resulting in inositol 1,4,5- ... B-thromboglobulin, vWF, fibrinogen, and coagulation factors V and XIII. ... Platelets release platelet-derived growth factor (PDGF), a potent chemotactic agent; and TGF beta, which stimulates the ...
Beta-thromboglobulin (β-thromboglobulin, also called Pro-Platelet basic protein) is a protein that is stored in alpha-granules ... Beta-Thromboglobulin also affects megakaryocyte maturation, and thus helps in regulating platelet production. Levels of Beta- ... Cytokines & Cells Online Pathfinder Encyclopaedia Beta-Thromboglobulin Retrieved on August 17, 2009 Pillai MM, Iwata M, ... Thromboglobulin is used to index platelet activation. It is measured by ELISA in blood plasma or urine, and often in ...
Plasma beta-thromboglobulin is correlated with platelet adhesiveness to bovine endothelium in patients with diabetes mellitus ... Plasma beta-thromboglobulin is correlated with platelet adhesiveness to bovine endothelium in patients with diabetes mellitus. ... We measured simultaneous plasma beta-thromboglobulin (BTG) and adhesion of 51Cr-labelled, washed platelets to confluent, bovine ...
... beta-thromboglobulin; decreased levels of anti-factor Xa and antithrombin III, decreased antithrombin III activity, increased ...
beta-thromboglobulin. Medical browser ? *▲. *plate, lingual. *plate, metal. *plate, palatal. *plateau. *plateau development ...
DETECTION OF ENHANCED INVIVO PLATELET ALPHA-GRANULE RELEASE IN DIFFERENT PATIENT GROUPS - COMPARISON OF BETA-THROMBOGLOBULIN, ... DETECTION OF ENHANCED INVIVO PLATELET ALPHA-GRANULE RELEASE IN DIFFERENT PATIENT GROUPS - COMPARISON OF BETA-THROMBOGLOBULIN, ... DETECTION OF ENHANCED INVIVO PLATELET ALPHA-GRANULE RELEASE IN DIFFERENT PATIENT GROUPS - COMPARISON OF BETA-THROMBOGLOBULIN, ...
... "beta-Thromboglobulin" by people in this website by year, and whether "beta-Thromboglobulin" was a major or minor topic of these ... Measurement of beta-thromboglobulin in biological fluids by radioimmunoassay is used for the diagnosis and assessment of ... "beta-Thromboglobulin" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical ... Below are the most recent publications written about "beta-Thromboglobulin" by people in Profiles. ...
Human Beta-Thromboglobulin (bTG) ELISA Kit *. Detection Target: Beta-Thromboglobulin (bTG). *. Reactivity: Human ...
beta-thromboglobulin - g { O u A -TG bicoid r R C h ... beta amyloid precursor protein ??A ~ C h O ?? ^ p N beta ... beta-adrenergic receptor kinase - A h i e ̃L i [ [ A ARK ... transforming growth factor-beta g X t H [ ~ O q trans-Golgi ...
A Biochemical Study on the Effect of Proteolysis of Beta-Thromboglobulin Proteins Released from Activated Platelets on ... A Biochemical Study on the Effect of Proteolysis of Beta-Thromboglobulin Proteins Released from Activated Platelets on ...
beta-thromboglobulin [ Time Frame: baseline ]. Determine whether patients with pre-dialysis stages 4-5 chronic kidney disease, ... as compared to those with normal renal function, have different platelet function as measured by beta-thromboglobulin. ...
Looking for online definition of C-X-C motif chemokine 7 in the Medical Dictionary? C-X-C motif chemokine 7 explanation free. What is C-X-C motif chemokine 7? Meaning of C-X-C motif chemokine 7 medical term. What does C-X-C motif chemokine 7 mean?
0/beta-Thromboglobulin; 0/fibrin fragment D; 26171-23-3/Tolmetin; 66635-83-4/Ketorolac; 9000-94-6/Antithrombin III; EC 3.4.-/ ... an enhanced lytic state concurrent with an enhanced activation of coagulation and diminished platelet activation although beta- ...
Blood was sampled before and after exercise to measure plasma and serum thromboxane B2 (TXB2), plasma beta-thromboglobulin (BTG ...
Beta thromboglobulin like protein. *C-X-C motif chemokine 8. *CEF-4 ...
beta endothelial cell derived neutrophil activating peptide. *beta thromboglobulin like protein. *C X C motif chemokine ligand ...
Characterization of the human beta-thromboglobulin gene. Comparison with the gene for platelet factor 4. (PMID: 1826003) ... Novel C-terminally truncated isoforms of the CXC chemokine beta- thromboglobulin and their impact on neutrophil functions. ( ... Proteolytic removal of residues 1-13 produces the active peptide beta-thromboglobulin, which is released from platelets along ... connective tissue activating peptide III,including platelet basic protein,precursor of beta thromboglobulin and neutrophil ...
... platelet factor-4 or beta-thromboglobulin did not differ between patients and controls. During exercise beta-thromboglobulin ...
thromboglobulin, beta-1. Limitations. This product is for research use only and is not approved for use in humans or in ...
... we measured simultaneous plasma beta-thromboglobulin (BTG) and fibrinopeptide A (FPA) in 40 insulin-dependent patients without ...
V. Rasi, T. Torstila, E. Ikkala, Beta-thromboglobulin in acute myocardial infarction . Acta Med. Scand. (SuppL) 642:85 (1980). ...
This family also includes platelet factor 4 and beta-thromboglobulin. MIPs affect a wide array of cell types and are important ... This family also includes platelet factor 4 and beta-thromboglobulin. MIPs affect a wide array of cell types and are important ... MIP-1 beta from rat recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), cell culture tested * pricing ... MIP-1 beta (CCL4) human recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), cell culture tested * pricing ...
Plasma beta-thromboglobulin to platelet factor 4 ratios as indices of vascular complications in essential hypertension GOMI T. ... Beta-thromboglobulin plasma levels in different stages of arterial hypertension PETRALITO A. ... Effects of prazosin on platelet aggregation and plasma beta-thromboglobulin in essential hypertension IKEDA T. ... The release, distribution, and clearance of human beta-thromboglobulin and platelet factor 4 DAWES J. ...
Beta-thromboglobulin and fibrinopeptide A in diabetes mellitus as markers of vascular damage. Acta Diabetol Lat 1985; 22: 39- ...
... and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; ...
Beta-thromboglobulin: a specific marker of in vivo platelet release reaction. Thromb Haemost. 1980;44:23-29. ... Kaplan KL, Owen J. Plasma levels of beta-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood ... Fréden K, Lundborg P, Vilén L, Kutti J. The peripheral platelet count in response to adrenergic alpha- and beta-1-receptor ... Jelsema CL, Axelrod J. Stimulation of phospholipase A2 activity in bovine rod outer segments by the beta gamma subunits of ...
  • We measured simultaneous plasma beta-thromboglobulin (BTG) and adhesion of 51Cr-labelled, washed platelets to confluent, bovine aortic endothelial monolayers in 50 insulin-dependent diabetic patients and 30 normal subjects (respective mean ages (+/- SD) = 45.1 +/- 16.4 and 45.8 +/- 17.2 years). (mysciencework.com)
  • Exemplary members of the family include the colony-stimulating factors (GM-CSF, M-CSF, G-CSF, interleukin-3), the interleukins (IL-1, IL-2, IL-11), the interferons (alpha, beta and gamma), the tumor necrosis factors (alpha and beta) and erythropoietin. (google.com)
  • 20-22 PF4 exists as a tetramer with the three beta sheets of each subunit facing inwards and the N- and C-termini lying on the surface of the molecule. (bloodjournal.org)
  • Effect of angiotensin converting enzyme inhibitors and beta-blockers on left ventricular remodeling after coronary artery bypass graft surgery. (nih.gov)
  • PF4 (platelet factor 4) and BTG (beta - thromboglobulin) were determined in plasma from the umbilical artery.Results: The concentration of PF4 was higher in male newborns (89.55 IU/ml) than in female newborns (77.22 IU/ml). (medscimonit.com)
  • After the operation there was a significant and progressive increase (p less than 0.01) in PF4 and beta-TG, and the presence of circulating platelet aggregates was demonstrated. (cun.es)